TNFRSF8 and anaplastic large cell lymphoma: In a phase I dose escalation study of CD30 CAR-T cells by Ramos et al. (NCT01316146), one of two enrolled ALCL patients achieved CR, and no CAR-T infusion-related toxicities were observed [163].